Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Voyager Therapeutics Inc (VYGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8306
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its clinical candidate, VY-AADC, currently under open-label Phase 1b clinical trials, is intended for the treatment of advanced Parkinson’s disease. Voyager’s preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; Tau program, for tauopathies including Alzheimer’s disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company offers development services in the areas such as vector optimization and engineering, dosing techniques, and process development and production, among others. Voyager is headquartered in Cambridge, Massachusetts, the US.

Voyager Therapeutics Inc (VYGR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Voyager Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Voyager Therapeutics Raises USD60 Million in Series B Financing 12
Voyager Therapeutics Raises US$45 Million In Series A Financing 13
Partnerships 14
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 14
Voyager Therapeutics Enters into Research Agreement with CHDI Foundation 16
Voyager Therapeutics Enters into Development Agreement with Genzyme 17
Voyager Therapeutics Enters into Agreement with MassBiologics 18
Licensing Agreements 19
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 19
Voyager Therapeutics Enters into Licensing Agreement with California Institute of Technology 20
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 21
Voyager Therapeutics Enters Into Licensing Agreement With University Of Massachusetts 23
Equity Offering 25
Voyager Therapeutics Raises USD62.1 Million in Public Offering of Shares 25
Voyager Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 27
Voyager Therapeutics Raises USD80.5 Million in IPO 28
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 30
Voyager Therapeutics Inc – Key Competitors 31
Voyager Therapeutics Inc – Key Employees 32
Voyager Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 07, 2018: Voyager Therapeutics announces second quarter 2018 financial results and corporate highlights 34
May 10, 2018: Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights 36
Mar 14, 2018: Voyager Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 38
Nov 02, 2017: Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights 40
Aug 08, 2017: Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights 43
May 09, 2017: Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights 46
Mar 15, 2017: Voyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights 48
Corporate Communications 51
Jun 28, 2018: Voyager Therapeutics Names Andre Turenne As President And Chief Executive Officer 51
May 29, 2018: Voyager Therapeutics Announces Management Change 53
Jan 31, 2018: Voyager Therapeutics Announces CEO Succession Plan for 2018 54
Sep 18, 2017: Voyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer 55
Jan 05, 2017: Voyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors 56
Jan 03, 2017: Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer 57
Product News 58
10/16/2018: Voyager Therapeutics announces preclinical data for Amyotrophic Lateral Sclerosis at the Congress of the European Society of Gene and Cell Therapy 58
Jul 17, 2017: Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain 59
02/13/2017: Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS) 60
Clinical Trials 61
May 17, 2018: Voyager Therapeutics Announces New Data on VY-SOD101 at the American Society of Gene and Cell Therapy 2018 Annual Meeting 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Voyager Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Voyager Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Voyager Therapeutics Raises USD60 Million in Series B Financing 12
Voyager Therapeutics Raises US$45 Million In Series A Financing 13
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 14
Voyager Therapeutics Enters into Research Agreement with CHDI Foundation 16
Voyager Therapeutics Enters into Development Agreement with Genzyme 17
Voyager Therapeutics Enters into Agreement with MassBiologics 18
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 19
Voyager Therapeutics Enters into Licensing Agreement with California Institute of Technology 20
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 21
Voyager Therapeutics Enters Into Licensing Agreement With University Of Massachusetts 23
Voyager Therapeutics Raises USD62.1 Million in Public Offering of Shares 25
Voyager Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 27
Voyager Therapeutics Raises USD80.5 Million in IPO 28
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 30
Voyager Therapeutics Inc, Key Competitors 31
Voyager Therapeutics Inc, Key Employees 32
Voyager Therapeutics Inc, Subsidiaries 33

List of Figures
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Voyager Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RCI Banque SA:企業の戦略的SWOT分析
    RCI Banque SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Oxiteno SA Industria E Comercio:企業の戦略的SWOT分析
    Oxiteno SA Industria E Comercio - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Sime Darby Bhd (SIME):電力:M&Aディール及び事業提携情報
    Summary Sime Darby Bhd (Sime Darby) is a trading and logistics company. It provides diversified products and services through its subsidiaries, affiliates, and joint ventures. The company cultivates oil palm, rubber and sugarcane; rears cattle; and produces oil and fats. It also imports, assembles, …
  • SBA Communications Corp (SBAC):企業の財務・戦略的SWOT分析
    Summary SBA Communications Corp (SBA) operates as a wireless communication infrastructure company . The company offers site leasing and site development services. It provides infrastructure solution such as towers, distributed antenna systems (DAS), buildings, rooftops and small cells. The company p …
  • Zoll Medical Corporation-医療機器分野:企業M&A・提携分析
    Summary ZOLL Medical Corporation (Zoll), a subsidiary of Asahi Kasei Corporation, is a provider of medical devices and software solutions for advance emergency care. The company designs, manufactures and markets resuscitation devices and systems used for resuscitation and acute critical care victims …
  • WAVE Life Sciences Ltd (WVE):製薬・医療:M&Aディール及び事業提携情報
    Summary WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company's pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and ant …
  • VIDA Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary VIDA Diagnostics Inc (VIDA) is a medical technology company that provides clinical imaging software and analysis services for early detection, evaluation, and treatment of pulmonary diseases. The company offers VIDA exchange and VIDA vision. Its products are used in airway mapping, lung volu …
  • AbbVie Inc (ABBV)-医療機器分野:企業M&A・提携分析
    Summary AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that carries out the research, development, manufacture and commercialization of advanced therapies to treat complex and serious diseases. The company focuses on providing drugs in immunology, cancer, neuroscience and virology …
  • Enzo Biochem Inc (ENZ):企業の製品パイプライン分析
    Summary Enzo Biochem Inc (Enzo Biochem) is a life sciences and biotechnology company with a focus on harnessing genetic processes for the development of research tools, therapeutics and diagnostics. It also provides reference laboratory services to the medical community. The company focuses on the d …
  • AveXis Inc (AVXS):製薬・医療:M&Aディール及び事業提携情報
    Summary AveXis Inc (AveXis), formerly BioLife Cell Bank Inc, is a biotechnology company that develops innovative treatments for rare and potentially fatal neurological genetic diseases. The company offers AVXS-101, a proprietary gene therapy candidate in phase 1 targeted at the treatment of spinal m …
  • Koln Dusseldorfer Deutsche Rheinschiffahrt Ag:企業の戦略・SWOT・財務分析
    Koln Dusseldorfer Deutsche Rheinschiffahrt Ag - Strategy, SWOT and Corporate Finance Report Summary Koln Dusseldorfer Deutsche Rheinschiffahrt Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • Birla Corporation Ltd:企業の戦略・SWOT・財務情報
    Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Agappe Diagnostics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Agappe Diagnostics Ltd (Agappe) is an in vitro diagnostic company that manufactures clinical chemistry and immuno turbidimetry products. The company’s products categories include biochemistry, immunochemistry, serology, coagulation, hematology, system reagents, controls and calibrators; poin …
  • Venture Life Group Plc (VLG)-製薬・医療分野:企業M&A・提携分析
    Summary Venture Life Group Plc (Venture Life) is a consumer goods company that offers ageing population products. The company's product range and pipeline comprise food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medica …
  • Clean Energy Fuels Corp (CLNE):石油・ガス:M&Aディール及び事業提携情報
    Summary Clean Energy Fuels Corp (Clean Energy) is an oil and gas company that offers natural gas fuel transportation services. The company’s products fuels, liquefied natural gas, compressed natural gas, renewable natural gas, and bulk fuels. It also provides storage systems, compressors, dispensers …
  • Dong Wha Pharma Co Ltd (000020):企業の財務・戦略的SWOT分析
    Summary Dong Wha Pharma Co Ltd (Dongwha Pharm) is a pharmaceutical company that offers generic products. The company offers ethical drugs, over-the-counter products, cosmetics, health foods, medical devices, and food and drinks. Its products comprise clzapine tablets, valaboom, aripico tablets, intr …
  • The Lubrizol Corp:企業の戦略的SWOT分析
    The Lubrizol Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Tate & Lyle PLC:企業のM&A・事業提携・投資動向
    Tate & Lyle PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tate & Lyle PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Pharmacyclics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmacyclics Inc (Pharmacyclics), a wholly-owned subsidiary of AbbVie, discovers, develops and commercializes novel therapies for the treatment of cancer and immunemediated diseases. The company’s drugs and drug candidates are synthetic small-molecules that target major biochemical pathways …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆